.Pharmacolibrary.Drugs.ATC.L.L01AD04 .Pharmacolibrary.Drugs.ATC.L.L01AD04| name: | Streptozocin |
| ATC code: | L01AD04 | route: | intravenous |
| n-compartments | 2 |
Streptozocin is an antineoplastic agent belonging to the nitrosourea class. It is specifically used for the treatment of pancreatic islet cell carcinoma (pancreatic neuroendocrine tumors). Streptozocin is an alkylating agent approved for clinical use but mainly reserved for rare tumors due to its toxicity profile.
Pharmacokinetic parameters observed in adult patients with metastatic islet cell carcinoma receiving intravenous infusion.
Kim, YC, et al., & Lee, MG (2008). Pharmacokinetics of phenytoin and its metabolite, 4'-HPPH, after intravenous and oral administration of phenytoin to diabetic rats induced by alloxan or streptozotocin. Biopharmaceutics & drug disposition 29(1) 51–61. DOI:10.1002/bdd.591 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18022993
Engler, FA, et al., & Balthasar, JP (2014). Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy. Pharmaceutical research 31(5) 1185–1193. DOI:10.1007/s11095-013-1241-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/24203494
Chen, T, et al., & Mager, DE (2013). Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats. Journal of pharmaceutical sciences 102(10) 3844–3851. DOI:10.1002/jps.23682 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23897494